Tag: Juno Therapeutics (JUNO)

Yesterday’s Market Performance Brings Back Hope to Normalcy.  Compugen Announced Some Encouraging News

Yesterday’s Market Performance Brings Back Hope to Normalcy. Compugen Announced Some Encouraging News

Stories from Yesterday’s Market We are not claiming that the market volatility has subsided and the leadership has shown and is in full control of the chaos. But yesterday biotech stock performance made us feel that investors are regaining their common sense and trying to benefit from the catastrophic plummeting of the member firms stock prices. Today’s trading seems negative for the biotech stocks, but …
Prohost Letter #383

Prohost Letter #383

Prohost Letter #383 The Market - Recent tails about the market and the biotech sector are true thrillers. By true we mean no-fiction. The accounts lack common sense. Professionals' interpretations of the stocks' and of the market's moves are bizarre and misleading. General investors complain only when the stocks' volatility gets out of hand, yet, do not object to the hype, or interferes against the baseless …
NantKwest Inc:  A Novel Breathtaking Immunotherapy for Cancer?

NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some called it the “New Golden Boy”. During the IPO, investors who knew about this firm and were waiting for that day seemed confident that the stock would surge. As a matter of fact, the stock did surge. On July 27, NantKwest, Inc. (formerly Conkwest, Inc.), Issued a press release …
Prohost Letter #380

Prohost Letter #380

Prohost Letter #380 Investors Concerns, Excitments and Expectations PART 2  REGENERON On Friday, July 24, Regeneron (REGN) stock closed at $541.l85 DOWN $14.76. The reason for loss was good news announcing that the FDA approved its cholesterol-lowering drug Praluent! Before the unreasonable sell on good news phenomenon, Regeneron had scored a new all time high on proven accomplishments (Read articles posted in past Prohost Letters). …
Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles

Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles

Today it is Greece. What About Tomorrow? Can Greece’s crisis devastate the biotech sector? No sane individual would think so and the hysteria cannot be called other than what it is. The biotech sector is not overvalued and its value must not be insulted by unfairly downgrading great biotech revolutionary firms, while they are obviously undervalued. Those who invest their money against biotech stocks regardless …
Prohost Letter #378 Part 2

Prohost Letter #378 Part 2

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The ASCO meeting projected the huge advancement in the understanding, diagnosing and treating cancer. What looked as if a sudden explosion has brought in the big change, the change was, in fact a slow, deep-rooted evolution, built up over a long period of trial and error with the failures constituting …
Prohost Letter #378 Part 1

Prohost Letter #378 Part 1

Prohost Letter #378 Part 1 Views and Visions TOP-TIER BIOTECHNOLOGY COMPANIES GILEAD We wrote a lot about Gilead (GILD), doing our best to protect investors against negative gossip that filled the media and aimed at misleading and insulting investors’ intelligence. We never lowered our target based on the perpetrated, fabricated stories, which made many investors lose confidence in Gilead’s strategy and sell their stocks, thus, …
Immunotherapy at ASCO. What Do We Want to Hear?

Immunotherapy at ASCO. What Do We Want to Hear?

For those who ask whether immunotherapy will have a dominant presence at ASCO, we confirm that yes; immunotherapy therapeutics will have a presence and a lot of audience, especially oncologists. There is big reason for oncologists’ interest in the subject. Their patients who have exhausted all standard of care treatments and would usually go home to die, did not lose hope this time. Instead, many …
Prohost Letter #377

Prohost Letter #377

Prohost Letter #377 PICKING BIOTECH FIRMS Before Investing in Them Raising the bar in designating small drug developing firms as biotechnology firms has occurred several times since 2011. In that year, many technologies were tremendously enhanced, which enabled them to realize superior goals, i.e., produce safer and more effective breakthrough drugs for chronic debilitating and life-threatening diseases. Prohost Portfolios picks, which have outperformed other industries’ …
Prohost Letter #375 Part 2

Prohost Letter #375 Part 2

Prohost Letter #375 Part 2 Novel Breakthrough Cancer Immunotherapy Approaches PART 2 In Part 1 of this issue, we described the immunotherapy approach that aims at modulating immune checkpoint proteins, thus unleashing the T cells to do their natural task of detecting, attacking and eliminating cancer cells. The approach is a success, as we reiterated, with greatly encouraging results. Researchers in large oncology centers and drug …